60 related articles for article (PubMed ID: 8276427)
1. Structure-activity relationship studies of 4-substituted-2-guanidinothiazoles: reversible inhibitors of gastric (H+/K+)-ATPase.
Ojha TN; Singh P; Sharma RC
Indian J Biochem Biophys; 1993 Aug; 30(4):239-43. PubMed ID: 8276427
[TBL] [Abstract][Full Text] [Related]
2. Antiulcer agents. 4-substituted 2-guanidinothiazoles: reversible, competitive, and selective inhibitors of gastric H+,K(+)-ATPase.
LaMattina JL; McCarthy PA; Reiter LA; Holt WF; Yeh LA
J Med Chem; 1990 Feb; 33(2):543-52. PubMed ID: 2153817
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.
Terauchi H; Tanitame A; Tada K; Nakamura K; Seto Y; Nishikawa Y
J Med Chem; 1997 Jan; 40(3):313-21. PubMed ID: 9022797
[TBL] [Abstract][Full Text] [Related]
4. 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors.
Yamada M; Yura T; Morimoto M; Harada T; Yamada K; Honma Y; Kinoshita M; Sugiura M
J Med Chem; 1996 Jan; 39(2):596-604. PubMed ID: 8558532
[TBL] [Abstract][Full Text] [Related]
5. Cyclo-oxygenase-1 inhibition increases acid secretion by modulating H+,K+-ATPase expression and activation in rabbit parietal cells.
Nandi J; Das PK; Zinkievich JM; Baltodano JD; Levine RA
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):127-34. PubMed ID: 18759857
[TBL] [Abstract][Full Text] [Related]
6. Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Buhr W; Brehm C; Palmer AM; Feth MP; Senn-Bilfinger J; Simon WA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5374-8. PubMed ID: 17723299
[TBL] [Abstract][Full Text] [Related]
7. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.
Smolka AJ; Goldenring JR; Gupta S; Hammond CE
BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114
[TBL] [Abstract][Full Text] [Related]
9. The unique ultrastructure of secretory membranes in gastric parietal cells depends upon the presence of H+, K+ -ATPase.
Miller ML; Judd LM; Van Driel IR; Andringa A; Flagella M; Bell SM; Schultheis PJ; Spicer Z; Shull GE
Cell Tissue Res; 2002 Sep; 309(3):369-80. PubMed ID: 12195293
[TBL] [Abstract][Full Text] [Related]
10. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Shin JM; Cho YM; Sachs G
J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and identification of a new class of antileukemic agents containing 2-(arylcarboxamide)-(S)-6-amino-4,5,6,7-tetrahydrobenzo[d]thiazole.
Prasanna DS; Kavitha CV; Vinaya K; Ranganatha SR; Raghavan SC; Rangappa KS
Eur J Med Chem; 2010 Nov; 45(11):5331-6. PubMed ID: 20855133
[TBL] [Abstract][Full Text] [Related]
12. Comparative QSAR modeling of COX-2 inhibitor 1,2-diarylimidazoles using E-state and physicochemical parameters.
Chakraborty S; Sengupta C; Roy K
Indian J Biochem Biophys; 2007 Jun; 44(3):169-75. PubMed ID: 17650586
[TBL] [Abstract][Full Text] [Related]
13. Novel pyrimidines as acid pump antagonists (APAs).
Yoon YA; Park CS; Cha MH; Choi H; Sim JY; Kim JG
Bioorg Med Chem Lett; 2010 Oct; 20(19):5735-8. PubMed ID: 20810280
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
15. Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Brehm C; Buhr W; Palmer AM; Volz J; Simon WA
Bioorg Med Chem; 2008 Jan; 16(1):536-41. PubMed ID: 17964794
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor and ion binding sites on the gastric H,K-ATPase.
Munson K; Garcia R; Sachs G
Biochemistry; 2005 Apr; 44(14):5267-84. PubMed ID: 15807521
[TBL] [Abstract][Full Text] [Related]
17. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
18. Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).
Bailey N; Bamford MJ; Brissy D; Brookfield J; Demont E; Elliott R; Garton N; Farre-Gutierrez I; Hayhow T; Hutley G; Naylor A; Panchal TA; Seow HX; Spalding D; Takle AK
Bioorg Med Chem Lett; 2009 Jul; 19(13):3602-6. PubMed ID: 19467868
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells.
Suri-Payer E; Kehn PJ; Cheever AW; Shevach EM
J Immunol; 1996 Aug; 157(4):1799-805. PubMed ID: 8759770
[TBL] [Abstract][Full Text] [Related]
20. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
Andersson K; Carlsson E
Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
